New drug cocktail offers hope for relapsed t-cell blood cancers

NCT ID NCT06207123

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 27 times

Summary

This study tests a new experimental drug, LP-118, combined with three other medicines (ponatinib, vincristine, and dexamethasone) in adults with T-cell acute lymphoblastic leukemia or lymphoma that has come back or not responded to treatment. The main goals are to find a safe dose and see if the combination can put the cancer into remission. About 15 participants will be enrolled at the University of Chicago.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Chicago Medicine Comprehensive Cancer Center

    RECRUITING

    Chicago, Illinois, 60615, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Rochester Medical Center, Wilmot Cancer Center

    RECRUITING

    Rochester, New York, 14642, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.